Novel therapeutics

#Biotherapeutics #Drug development #Drug discovery #Novel therapeutics

Infex’s resistance bypass drug program ready for clinic

Infex Therapeutics has appointed Pharmaron to help progress its MET-X program which targets urinary tract infections caused by World Health Organisation (WHO) critical-priority resistant Gram-negative bacteria. Pharmaron will manufacture the patented molecule at its plant in Hoddesdon, Hertfordshire. On completion of this stage of the work, MET-X will go through… Read More

#News

#Cancer #Clinical trial #Life sciences #Novel therapeutics #Oncology

SignalChem collaborates with Merck on advanced non-small cell lung cancer

SignalChem Lifesciences, a clinical-stage company who develop novel targeted therapies for oncology, has announced its collaboration with Merck, through a subsidiary, to evaluate the combination of SLC-391, a selective AXL inhibitor developed by SignalChem, with KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 therapy, in patients with advanced non-small cell lung cancer (NSCLC). AXL,… Read More

#Cancer Research #News

#Antibody response #Biologics #Drug targets #Novel therapeutics #RNA #siRNA

Sitting down with…Michael Smyth, Galapagos UK

Michael Smyth is Medical Director at Galapagos UK, responsible for launching innovative therapies in the UK to help change the course of inflammatory disease for patients. Having studied medicine at Liverpool University, one of his personal missions is lifelong learning which is reflected in his role to strive for new treatment… Read More

#Editor's Choice #News #Opinion

#Antibodies #Covid-19 #Novel therapeutics

Fusion Antibodies and Queen’s University get grant to develop COVID-19 antibodies

Fusion Antibodies, pre-clinical antibody discovery, engineering and supply experts, and Queen’s University Belfast, have been awarded a £453,000 grant from Invest Northern Ireland to further expand their COVID-19 targeted research and development efforts. Within the framework of their Northern Ireland Coronavirus Antibody Development Alliance (NICADA), the two organisations will use… Read More

#Covid-19 #Editor's Choice #News